synthetic lethal metabolic targeting cellular senescence cancer therapy 
activated oncogenes anticancer chemotherapy induce cellular senescence terminal growth arrest viable cells characterized s-phase entry-blocking histone lysine trimethylation h3k9me3 although therapy-induced senescence tis improves long-term outcomes potentially harmful properties senescent tumour cells make quantitative elimination therapeutic priority use em-myc transgenic mouse lymphoma model tis depends h3k9 histone methyltransferase suv39h1 show mechanism therapeutic exploitation senescence-related metabolic reprogramming vitro vivo senescence-inducing chemotherapy tis-competent lymphomas tis-incompetent suv39h1- lymphomas show increased glucose utilization much higher atp production demonstrate linked massive proteotoxic stress consequence senescence-associated secretory phenotype sasp described previously- sasp-producing tis cells exhibited endoplasmic reticulum stress unfolded protein response upr increased ubiquitination thereby targeting toxic proteins autophagy acutely energy-consuming fashion accordingly tis lymphomas unlike senescence models lack strong sasp response sensitive blocking glucose utilization autophagy led selective elimination caspase--and caspase--mediated endoplasmic-reticulum-related apoptosis consequently pharmacological targeting metabolic demands tis induction vivo prompted tumour regression improved treatment outcomes findings unveil hypercatabolic nature tis therapeutically exploitable synthetic lethal metabolic targeting 
